Literature DB >> 24983663

Development of first lead structures for phosphoinositide 3-kinase-C2γ inhibitors.

Anne Freitag1, Prajwal Prajwal, Aliaksei Shymanets, Christian Harteneck, Bernd Nürnberg, Christoph Schächtele, Michael Kubbutat, Frank Totzke, Stefan A Laufer.   

Abstract

The importance of complete elucidation of the biological functions of phosphoinositide 3-kinases (PI3K) was realized years ago. They generate 3-phosphoinositides, which are known to function as important second messengers in many inter- and intracellular signaling pathways. However, the functional role of class II PI3Ks is still unclear. Herein, we describe the synthesis of a panel of compounds that were tested against all eight mammalian PI3K-isoforms. We found inhibitors with some selectivity for class II PI3K-C2γ and also compounds with preferred inhibition of class II PI3K-C2β, providing structural leads to develop selective tool compounds.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24983663     DOI: 10.1021/jm5006034

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Class II but Not Second Class-Prospects for the Development of Class II PI3K Inhibitors.

Authors:  Simon J Mountford; Zhaohua Zheng; Krithika Sundaram; Ian G Jennings; Justin R Hamilton; Philip E Thompson
Journal:  ACS Med Chem Lett       Date:  2014-09-24       Impact factor: 4.345

Review 2.  Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy.

Authors:  Xinlei Yu; Yun Chau Long; Han-Ming Shen
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

3.  Identification of DNA methylation patterns and biomarkers for clear-cell renal cell carcinoma by multi-omics data analysis.

Authors:  Pengfei Liu; Weidong Tian
Journal:  PeerJ       Date:  2020-08-03       Impact factor: 2.984

Review 4.  Phosphatidylinositol 3-phosphates-at the interface between cell signalling and membrane traffic.

Authors:  Andrea L Marat; Volker Haucke
Journal:  EMBO J       Date:  2016-02-17       Impact factor: 11.598

5.  Different inhibition of Gβγ-stimulated class IB phosphoinositide 3-kinase (PI3K) variants by a monoclonal antibody. Specific function of p101 as a Gβγ-dependent regulator of PI3Kγ enzymatic activity.

Authors:  Aliaksei Shymanets; Oscar Vadas; Cornelia Czupalla; Jaclyn LoPiccolo; Michael Brenowitz; Alessandra Ghigo; Emilio Hirsch; Eberhard Krause; Reinhard Wetzker; Roger L Williams; Christian Harteneck; Bernd Nürnberg
Journal:  Biochem J       Date:  2015-07-01       Impact factor: 3.857

Review 6.  PI3K inhibitors in thrombosis and cardiovascular disease.

Authors:  Tom N Durrant; Ingeborg Hers
Journal:  Clin Transl Med       Date:  2020-01-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.